花王股份(603007.SH):花種投資減持完畢 累計減持2%股份
格隆匯3月11日丨花王股份(603007.SH)公佈,本次減持計劃實施前,江蘇花種投資有限公司(以下簡稱“花種投資”)持有公司無限售流通股1924.34萬股,佔公司總股本的5.71%。上述股份來源為公司首次公開發行前取得的股份及上市後以資本公積金轉增股本方式取得的股份。
2019年12月27日至2020年3月11日期間,花種投資以大宗交易方式累計減持公司股份674.18萬股,佔公司總股本的2%。截止本公告披露日,花種投資持有公司無限售流通股1250.16萬股,佔公司總股本的3.71%。本次減持計劃已實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.